The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.
MedPage Today on MSN5d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid TumorsFDA approval of tarlatamab (Imdelltra) for small-cell lung cancer offers ... Another BiTE in development by Amgen binds CD3 ...
The approval positions Amgen’s Bkemv (formerly ABBP 959) as a key competitor to complement C5 inhibitor Soliris (eculizumab), which contributed $3.1 billion in global revenues to AZ last year.
Dr. Goss has received research funding from AstraZeneca and Roche Pharmaceuticals and has served as a paid consultant or been on an Advisory Board for Amgen, AstraZeneca, Pfizer Inc., and Roche ...
DLL3 was identified in over 70% of the tumors, highlighting its potential as a promising target for therapies like Tarlatamab. Another key finding involved TTF-1 expression; patients with ...
With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David R. Spigel, MD, is optimistic about the future of small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback